Transglutaminase 3 present in the IgA aggregates in dermatitis herpetiformis skin is enzymatically active and binds soluble fibrinogen

Journal of Investigative Dermatology

Volumn 135, Issue 2, 2015, Pages 623-625

  Taylor, Ted B ^a   Schmidt, Linda A ^a   Meyer, Laurence J ^a,b   Zone, John J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CADAVERINE; FIBRINOGEN; IMMUNOGLOBULIN A; TRANSGLUTAMINASE 3; UNCLASSIFIED DRUG; PROTEIN AGGREGATE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TGM3 PROTEIN, HUMAN;

DERMATITIS HERPETIFORMIS; ENZYME ACTIVITY; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; CHEMISTRY; ENZYMOLOGY; METABOLISM; SKIN;

DERMATITIS HERPETIFORMIS; FIBRINOGEN; HUMANS; IMMUNOGLOBULIN A; PROTEIN AGGREGATES; SKIN; TRANSGLUTAMINASES;

EID: 84925358098     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.368     Document Type: Letter

References (15)

1. Airola K, Vaalamo M, Reunala T et al. (1995) Enhanced expression of interstitial collagenase, stromelysin-1, and urokinase plasminogen activator in lesions of dermatitis herpetiformis. J Invest Dermatol 105:184-9
2. Cox NH, Friedmann PS (1991) Induction of lesions of dermatitis herpetiformis by autologous serum. Br J Dermatol 124:69-73
3. Davalos D, Akassoglou K (2012) Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 34:43-62
4. Hausch F, Halttunen T, Maki M et al. (2003) Design, synthesis, and evaluation of gluten peptide analogies selective inhibitors of human tissue transglutaminase. Chem Biol 10:225231
5. Huang EY, Wu H, Island ER et al. (2002) Differential expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in early and late gestational mouse skin and skin wounds. Wound Repair Regen 10:387-96
6. Iismaa SE, Mearns BM, Lorand L et al. (2009) Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev 89:991-1023
7. Jeitner TM, Delikatny EJ, Ahlqvist J et al. (2005) Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem Pharmacol 69:961-70
8. Lajemi M, Demignot S, Borge L et al. (1997) The use of Fluoresceincadaverine for detecting amine acceptor protein substrates accessible to active transglutaminase in living cells. Histochem J 29:593-606
9. Mustakallio KK, Blomqvist K, Laiho K (1970) Papillary deposition of fibrin, a characterisitic of initial lesions of dermatitis herpetiformis. Ann Clin Res 2:13-8
10. 3, fibrin and fibronectin in skin lesions in dermatitis herpetiformis. Br J Dermatol 105:167-77
11. Sardy M, Karpati S, Merkl B et al. (2002) Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 195:747-57
12. Shah SA, Ormerod AD (2000) Dermatitis herpetiformis effectively treated with heparin, tetracycline and nicotinamide. Clin Exp Dermatol 25:204-5
13. Silver FH, Siperko LM, Seehra GP (2003) Mechanobiology of force transduction in dermal tissue. Skin Res Technol 9:3-23
14. Tan CC, Sale JE, Brammer C et al. (1996) A rare case of dermatitis herpetiformis requiring parenteral heparin for long-term control. Dermatology 192:185-6
15. Zone JJ, Schmidt LA, Taylor TB et al. (2011) Dermatitis herpetiformis sera or goat anti-transglutaminase-3 transferred to human skingrafted mice mimics dermatitis herpetiformis immunopathology. J Immunol 186:4474-80